^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Kaitanni (cadonilimab) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Published date:
11/27/2023
Excerpt:
From Aug 2022 to Aug 2023, 22 pts were enrolled, of which 14 (63.6%) received cadonilimab (10mg/kg, q3w) plus SOX, 4 (18.2%) received cadonilimab (10mg/kg, q3w) plus XELOX and 3 (13.6%) received cadonilimab (6mg/kg, q2w) plus FOLFOX….This real-world analysis further confirmed the promising efficacy and safety of cadonilimab plus chemotherapy as first-line treatment in advanced G/GEJ cancer pts with PD-L1 CPS≤5.
Secondary therapy:
SOX; CAPOX; FOLFOX
